Inquiries persist about how safe Retaratrutrides multi-receptor approach may be considering specific concerns such as medullary thyroid cancer or kidney function results, particularly given that novel therapies always necessitate thorough scrutiny along ongoing research determination before cementing their roles within therapeutic disciplines.[full_image] Exenatide: The First Market Entrant Exenatide, a pioneer among the GLP-1 receptor agonists, heralded new possibilities in diabetes treatment when it hit the market
Dysesthesia: A New Signal for Retatrutide The TRIUMPH-4 Phase 3 trial revealed an unexpected finding: dysesthesia (abnormal touch sensations where normal sensations feel unusual or painful) in 20.9% of participants on 12 mg and 8.8% on 9 mg, compared to 0.7% on placebo (BioSpace, Dec 2025)
For the full list of side effects, look at the package insert that comes with your medication (find those here for Zepbound, Mounjaro, Wegovy, and Ozempic)
Despite this, it is increasingly being marketed online often alongside other metabolic compounds raising significant patient safety concerns